#FDA Approval #Liechtenstein #Vaduz #Implantica #RefluxStop

Implantica Reports Q2 2026: Growth and FDA Approval

Implantica, a dynamic player in the medtech industry, has published its interim report for the first half of 2026, exemplifying significant achievements and robust growth metrics. The period reflected an impressive growth trajectory, particularly in the sales of its flagship product, RefluxStop®, which saw a dramatic increase of over 60% compared to the same quarter last year. This growth underscores Implantica's successful strategy in capitalizing on key European markets.

Key Highlights from Q2 2026

1. Sales Growth: The company's net sales surged to TEUR 717, marking a 66% increase from TEUR 433 in the same quarter the previous year. This surge is attributable to continued demand for RefluxStop®, signaling strong market acceptance.
2. Clinical Validation: A significant milestone was also reached with the publication of the largest independent study on RefluxStop® to date in the renowned journal Nature's Scientific Reports. This study analyzed safety outcomes in 602 patients across 22 centers across six European nations, revealing that serious safety events and reoperations plummeted below 2%, a fantastic finding that enhances confidence in the product's safety and efficacy.
3. Strategic Developments: Implantica's strategic preparation has set the stage for commercial success, highlighted by new Italian cost-effectiveness data as well as the integration of a seventh InEK-reporting hospital in Germany, enhancing the company's reimbursement pathway.
4. Expansion into U.S. Market: After the end of the reporting period, Implantica secured FDA PMA approval for RefluxStop®, which opens the U.S. market and initiates U.S. commercial launch activities. Preparations for U.S. market entry are underway, with efforts being made to strengthen the organization's presence and to establish a comprehensive logistics and distribution framework.
5. European Market Expansion: Furthermore, Implantica's European footprint continues to grow, with ongoing establishment of Centers of Excellence. The 20th Center has opened in Spain at the esteemed MD Anderson Madrid, along with new sites in Switzerland and the UK, raising the total of European Centers to over 60. This expansion is crucial in reinforcing Implantica's market position across Europe.

Financial Overview

Over the first six months of the year, key financial metrics echo the performance trends observed in Q2:

• - Net Sales: Increased by 34% to TEUR 1,574 compared to TEUR 1,178 in the prior year.
• - Gross Margin: The adjusted gross margin maintained a strong position at 94%.
• - Operating Loss: The operating loss (EBIT) slightly decreased to TEUR 8,058 from TEUR 8,698, indicating improved operational efficiency.
• - Net Loss After Tax: Recorded at TEUR 8,267, a marginal increase from TEUR 8,212.
• - Cash Position: By the end of the reporting period, cash and cash equivalents totaled MEUR 41.7, reflecting a solid liquidity position to support ongoing endeavors.

Looking Ahead

Implantica's CEO, Peter Forsell, alongside other executives, will elaborate on these developments during a teleconference scheduled for August 21, 2026. The company aims to leverage these milestones to further enhance their market presence and capitalize on the opportunities presented by the FDA approval and expansion into the U.S. market.

Implantica continues to be at the forefront of innovation in medical technology, with its RefluxStop® product poised to transform the landscape of anti-reflux surgery. With an advanced product pipeline and strategic focus, Implantica is well-positioned for future growth and success in the medtech industry.

For more information, visit Implantica’s website.